SLC5A5 and neoplasm: In line with these pre-therapy in vivo and ex vivo studies, no significant effects on tumor growth and mouse survival were observed in the subcutaneous xenograft model after application of a therapeutic dose of 131I, while intrahepatic tumor-bearing mice showed a strong response to HIF-NIS-MSC/131I treatment as evidenced by reduced tumor growth, associated with reduced tumor cell proliferation as well as blood vessel density and tumor perfusion assessed by CEUS.